- Home
- GNLN vs XFOR Comparison
GNLN vs XFOR Comparison
Compare GNLN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- XFOR
- Stock Information
- Founded
- GNLN 2005
- XFOR 2014
- Country
- GNLN United States
- XFOR United States
- Employees
- GNLN N/A
- XFOR N/A
- Industry
- GNLN Durable Goods
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLN Consumer Discretionary
- XFOR Health Care
- Exchange
- GNLN Nasdaq
- XFOR Nasdaq
- Market Cap
- GNLN 12.9M
- XFOR 11.3M
- IPO Year
- GNLN 2019
- XFOR N/A
- Fundamental
- Price
- GNLN $3.30
- XFOR $3.92
- Analyst Decision
- GNLN
- XFOR Strong Buy
- Analyst Count
- GNLN 0
- XFOR 3
- Target Price
- GNLN N/A
- XFOR $71.17
- AVG Volume (30 Days)
- GNLN 134.8K
- XFOR 10.7M
- Earning Date
- GNLN 08-14-2025
- XFOR 08-08-2025
- Dividend Yield
- GNLN N/A
- XFOR N/A
- EPS Growth
- GNLN N/A
- XFOR N/A
- EPS
- GNLN N/A
- XFOR N/A
- Revenue
- GNLN $7,954,000.00
- XFOR $32,774,000.00
- Revenue This Year
- GNLN $1,541.21
- XFOR $1,300.08
- Revenue Next Year
- GNLN N/A
- XFOR N/A
- P/E Ratio
- GNLN N/A
- XFOR N/A
- Revenue Growth
- GNLN N/A
- XFOR 5721.31
- 52 Week Low
- GNLN $2.84
- XFOR $1.35
- 52 Week High
- GNLN $5,944.50
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- GNLN 40.38
- XFOR 72.25
- Support Level
- GNLN $3.13
- XFOR $2.45
- Resistance Level
- GNLN $3.92
- XFOR $3.42
- Average True Range (ATR)
- GNLN 0.39
- XFOR 0.50
- MACD
- GNLN 0.18
- XFOR 0.19
- Stochastic Oscillator
- GNLN 21.05
- XFOR 99.64
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.